{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:41:33Z","timestamp":1778596893534,"version":"3.51.4"},"reference-count":33,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2020,12,5]]},"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Given an increasing use of dipeptidyl peptidase-4 (DPP-4) inhibitors to treat patients with type 2 diabetes mellitus in the real-world setting, we conducted a prospective observational study (Japan-based Clinical Research Network for Diabetes Registry: J-BRAND Registry) to elucidate the safety and efficacy profile of long-term usage of alogliptin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Research design and methods<\/jats:title>\n                  <jats:p>We registered 5969 patients from April 2012 through September 2014, who started receiving alogliptin (group A) or other classes of oral hypoglycemic agents (OHAs; group B), and were followed for 3 years at 239 sites nationwide. Safety was the primary outcome. Symptomatic hypoglycemia, pancreatitis, skin disorders of non-extrinsic origin, severe infections, and cancer were collected as major adverse events (AEs). Efficacy assessment was the secondary outcome and included changes in hemoglobin A1c (HbA1c), fasting blood glucose, fasting insulin and urinary albumin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the registered, 5150 (group A: 3395 and group B: 1755) and 5096 (3358 and 1738) were included for safety and efficacy analysis, respectively. Group A patients mostly (&gt;90%) continued to use alogliptin. In group B, biguanides were the primary agents, while DPP-4 inhibitors were added in up to ~36% of patients. The overall incidence of AEs was similar between the two groups (42.7% vs 42.2%). Kaplan-Meier analysis revealed the incidence of cancer was significantly higher in group A than in group B (7.4% vs 4.8%, p=0.040), while no significant incidence difference was observed in the individual cancer. Multivariate Cox regression analysis revealed that the imbalanced patient distribution (more elderly patients in group A than in group B), but not alogliptin usage per se, contributed to cancer development. The incidence of other major AE categories was with no between-group difference. Between-group difference was not detected, either, in the incidence of microvascular and macrovascular complications. HbA1c and fasting glucose decreased significantly at the 0.5-year visit and nearly plateaued thereafter in both groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Alogliptin as a representative of DPP-4 inhibitors was safe and durably efficacious when used alone or with other OHAs for patients with type 2 diabetes in the real world setting.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjdrc-2020-001787","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T11:11:37Z","timestamp":1610536297000},"page":"e001787","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry)"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-8102","authenticated-orcid":false,"given":"Kohjiro","family":"Ueki","sequence":"first","affiliation":[{"name":"National Center for Global Health and Medicine, Diabetes Research Center, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Tanizawa","sequence":"additional","affiliation":[{"name":"Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Aichi Medical University School of Medicine, Nagakute, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Yamada","sequence":"additional","affiliation":[{"name":"Akita University Graduate School of Medicine, Akita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8261-2593","authenticated-orcid":false,"given":"Nobuya","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Watada","sequence":"additional","affiliation":[{"name":"Juntendo University Graduate School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iichiro","family":"Shimomura","sequence":"additional","affiliation":[{"name":"Osaka University Graduate School of Medicine, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rimei","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5909-3243","authenticated-orcid":false,"given":"Hideaki","family":"Miyoshi","sequence":"additional","affiliation":[{"name":"Hokkaido University Graduate School of Medicine, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Abiko","sequence":"additional","affiliation":[{"name":"Asahikawa Medical University, Asahikawa, Hokkaido, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Katagiri","sequence":"additional","affiliation":[{"name":"Tohoku University Graduate School of Medicine, Sendai, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Kanto Medical Center NTT EC, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3954-4983","authenticated-orcid":false,"given":"Akira","family":"Shimada","sequence":"additional","affiliation":[{"name":"Saitama Medical University Faculty of Medicine, Moroyama, Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Naruse","sequence":"additional","affiliation":[{"name":"Aichi Gakuin University School of Dentistry, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimpei","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Kochi University Medical School, Nankoku, Kochi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masazumi","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Saijo Central Hospital, Saijo, Ehime, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Shikata","sequence":"additional","affiliation":[{"name":"Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Okada","sequence":"additional","affiliation":[{"name":"University of Occupational and Environmental Health School of Medicine, Kitakyushu, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Araki","sequence":"additional","affiliation":[{"name":"Kumamoto University, Faculty of Life Sciences, Kumamoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, International University of Health and Welfare, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5428-3582","authenticated-orcid":false,"given":"Takashi","family":"Kadowaki","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan"},{"name":"Toranomon Hospital, Federation of National Public Service Personnel Mutual Aid Associations, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"2025073113040623000_9.1.e001787.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.02.023"},{"key":"2025073113040623000_9.1.e001787.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2016.04.016"},{"key":"2025073113040623000_9.1.e001787.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4711-2"},{"key":"2025073113040623000_9.1.e001787.4","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-S008"},{"key":"2025073113040623000_9.1.e001787.5","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-015-0033-2","article-title":"Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: post hoc analysis of the ASSET-K study","volume":"15","author":"Umezawa","year":"2015","journal-title":"BMC Endocr Disord"},{"key":"2025073113040623000_9.1.e001787.6","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/dom.12643","article-title":"Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus","volume":"18","author":"Del Prato","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2025073113040623000_9.1.e001787.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307684"},{"key":"2025073113040623000_9.1.e001787.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305889"},{"key":"2025073113040623000_9.1.e001787.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501352"},{"key":"2025073113040623000_9.1.e001787.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18269"},{"key":"2025073113040623000_9.1.e001787.11","doi-asserted-by":"crossref","first-page":"154295","DOI":"10.1016\/j.metabol.2020.154295","article-title":"The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes","volume":"109","author":"Stoian","year":"2020","journal-title":"Metabolism"},{"key":"2025073113040623000_9.1.e001787.12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i610"},{"key":"2025073113040623000_9.1.e001787.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62225-X"},{"key":"2025073113040623000_9.1.e001787.14","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12179"},{"key":"2025073113040623000_9.1.e001787.15","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0308"},{"key":"2025073113040623000_9.1.e001787.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004760","article-title":"Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry","volume":"4","author":"Inagaki","year":"2014","journal-title":"BMJ Open"},{"key":"2025073113040623000_9.1.e001787.17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s13340-015-0206-2","article-title":"Evidence-based practice guideline for the treatment for diabetes in Japan 2013","volume":"6","author":"Tajima","year":"2015","journal-title":"Diabetol Int"},{"key":"2025073113040623000_9.1.e001787.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01610.x"},{"key":"2025073113040623000_9.1.e001787.19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.02.018"},{"key":"2025073113040623000_9.1.e001787.20","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/1346-8138.14245","article-title":"Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid","volume":"45","author":"Chijiwa","year":"2018","journal-title":"J Dermatol"},{"key":"2025073113040623000_9.1.e001787.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e1369","article-title":"Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis","volume":"344","author":"Karagiannis","year":"2012","journal-title":"BMJ"},{"key":"2025073113040623000_9.1.e001787.22","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/pds.4560","article-title":"Association between dipeptidyl peptidase-4 inhibitors and urinary tract infection in elderly patients: a retrospective cohort study","volume":"27","author":"Imatoh","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025073113040623000_9.1.e001787.23","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients","volume":"154","author":"Kridin","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2025073113040623000_9.1.e001787.24","doi-asserted-by":"crossref","unstructured":"Kridin K , Cohen AD . Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid: a systematic review and meta-analysis. J Am Acad Dermatol 2018;S0190-9622:32660-4.doi:10.1016\/j.jaad.2018.09.048","DOI":"10.1016\/j.jaad.2018.09.048"},{"key":"2025073113040623000_9.1.e001787.25","doi-asserted-by":"publisher","DOI":"10.2337\/db12-1686"},{"key":"2025073113040623000_9.1.e001787.26","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jid.2017.11.023","article-title":"HLA-DQB1*03:01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP-4 inhibitors","volume":"138","author":"Ujiie","year":"2018","journal-title":"Journal of Investigative Dermatology"},{"key":"2025073113040623000_9.1.e001787.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"2025073113040623000_9.1.e001787.28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"The Lancet"},{"key":"2025073113040623000_9.1.e001787.29","doi-asserted-by":"publisher","DOI":"10.2337\/diab.44.11.1249"},{"key":"2025073113040623000_9.1.e001787.30","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025073113040623000_9.1.e001787.31","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00125-012-2827-3","article-title":"Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis","volume":"56","author":"Kim","year":"2013","journal-title":"Diabetologia"},{"key":"2025073113040623000_9.1.e001787.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2017.03.024"},{"key":"2025073113040623000_9.1.e001787.33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s13340-018-0346-2","article-title":"The current status of treatment-related severe hypoglycemia in Japanese patients with diabetes mellitus: a report from the committee on a survey of severe hypoglycemia in the Japan Diabetes Society","volume":"9","author":"Namba","year":"2018","journal-title":"Diabetol Int"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2020-001787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T20:04:16Z","timestamp":1753992256000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2020-001787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,13]]},"published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1136\/bmjdrc-2020-001787"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2020-001787","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}